Women discontinue antihypertensive drug therapy more than men. Evidence from an Italian population-based study.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
pubmed:
30
8
2019
medline:
15
12
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
Several factors affect adherence to antihypertensive drug treatment, but whether these factors include a sex difference is unclear. Aim of the study was to compare persistence with antihypertensive drug therapy between men and women in a large cohort of patients. The 60 526 residents of the Italian Lombardy Region aged 40-80 years newly treated with antihypertensive drugs during 2010 were identified and followed for 1 year after the first prescription. Discontinuation of treatment was defined as lack of prescription renewal for at least 90 days. Log-binomial regression models were fitted to estimate the risk ratio of treatment discontinuation in relation to sex. Other than for the whole population, analyses were stratified according to age, comorbidity status and the initial antihypertensive treatment strategy. Thirty-seven percent of the patients discontinued the drug treatment during follow-up. Compared with women, men had a 10% lower risk of discontinuation of drug treatment (95% confidence interval: 8-12). Persistence on antihypertensive treatment was better in men than in women, this being the case in both younger (40-64 years) and older patients (65-80 years), in patients starting treatment with any major antihypertensive drug and in patients who had a low comorbidity status. There was no evidence that men and women had a different risk of treatment discontinuation when their comorbidity status was worse, or initial antihypertensive treatment was based on drug combinations. Our data show that in a real-life setting, men are more persistent to antihypertensive drug therapy than women.
Identifiants
pubmed: 31464801
doi: 10.1097/HJH.0000000000002222
pii: 00004872-202001000-00021
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-149Références
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387:957–967.
Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 2015; 116:1058–1073.
Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20:1461–1464.
Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43:10–17.
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22:11–19.
Volpe M, Tocci G, Trimarco B, Rosei EA, Borghi C, Ambrosioni E, et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25:1491–1498.
Banegas JR, Segura J, Ruilope LM, Luque M, García-Robles R, Campo C, et al. CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43:1338–1344.
Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160:41–46.
Mazzaglia G, Mantovani L, Sturkenboom MC, Filippi A, Trifirò G, Cricelli C, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23:2093–2100.
Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007; 20:72–80.
Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly treated patients: a population-based study in Italy. J Hypertens 2008; 26:819–824.
Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Boström KB, et al. Persistence to antihypertensive drug classes: a cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD). Medicine (Baltimore) 2016; 95:e4908.
Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014; 32:1708–1715.
Lagi A, Rossi A, Passaleva MT, Cartei A, Cencetti S. Compliance with therapy in hypertensive patients. Intern Emerg Med 2006; 1:204–208.
Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and lifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015; 28:1209–1221.
Midy F, Rudnichi A. The impact of cardiovascular profile on persistence associated with antihypertensive medications. Int J Clin Pract 2013; 67:1334–1341.
Tajeu GS, Kent ST, Kronish IM, Huang L, Krousel-Wood M, Bress AP, et al. Trends in antihypertensive medication discontinuation and low adherence among Medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 2016; 68:565–575.
Grimmsmann T, Himmel W. Comparison of therapy persistence for fixed versus free combination antihypertensives: a retrospective cohort study. BMJ Open 2016; 6:e011650.
Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14:795–803.
Selmer R, Blix HS, Landmark K, Reikvam A. Choice of initial antihypertensive drugs and persistence of drug use: a 4-year follow-up of 78,453 incident users. Eur J Clin Pharmacol 2012; 68:1435–1442.
Corrao G, Mancia G. Generating evidence from computerized healthcare utilization databases. Hypertension 2015; 65:490–498.
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610–618.
Corrao G, Rea F, Ghirardi A, Soranna D, Merlino L, Mancia G. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66:742–749.
Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11:44–47.
Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010; 28:1584–1590.
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15:565–574. discussion 575-577.
Corrao G, Rea F, Monzio Compagnoni M, Merlino L, Mancia G. Protective effects of antihypertensive treatment in patients aged 85 years or older. J Hypertens 2017; 35:1432–1441.
Corrao G, Rea F, Di Martino M, De Palma R, Scondotto S, Fusco D, et al. Developing and validating a novel multisource comorbidity score from administrative data: a large population-based cohort study from Italy. BMJ Open 2017; 7:e019503.
Cohen JS. Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians’ Desk Reference. Arch Intern Med 2001; 161:880–885.
Rea F, Pagan E, Monzio Compagnoni M, Cantarutti A, Pugni P, Bagnardi V, Corrao G. Joinpoint regression analysis with time-on-study as time-scale. Application to three Italian population-based cohort studies. EBPH 2017; 14:e12616–e12621.
Degli Esposti L, Sangiorgi D, Buda S, Degli Esposti E, Scaglione F. Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ’real-world’ retrospective cohort study. BMJ Open 2016; 6:e012003.
Costa FV, Degli Esposti L, Cerra C, Veronesi C, Buda S. Trends in prescription and determinants of persistence to antihypertensive therapy: the PAPEETE study. High Blood Press Cardiovasc Prev 2009; 16:167–176.
Poluzzi E, Strahinja P, Vargiu A, Chiabrando G, Silvani MC, Motola D, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005; 61:603–609.
Haidinger T, Zweimüller M, Stütz L, Demir D, Kaider A, Strametz-Juranek J. Effect of gender on awareness of cardiovascular risk factors, preventive action taken, and barriers to cardiovascular health in a group of Austrian subjects. Gend Med 2012; 9:94–102.
Mosca L, Mochari-Greenberger H, Dolor RJ, Newby LK, Robb KJ. Twelve-year follow-up of American women's awareness of cardiovascular disease risk and barriers to heart health. Circ Cardiovasc Qual Outcomes 2010; 3:120–127.
Jarvie JL, Foody JM. Recognizing and improving health care disparities in the prevention of cardiovascular disease in women. Curr Cardiol Rep 2010; 12:488–496.
Chetty R, Stepner M, Abraham S, Lin S, Scuderi B, Turner N, et al. The association between income and life expectancy in the United States, 2001–2014. JAMA 2016; 315:1750–1766. Erratum in: JAMA. 2017;317:90.
Yeşil S, Yeşil M, Bayata S, Postaci N. ACE inhibitors and cough. Angiology 1994; 45:805–808.
Corrao G, Zambon A, Parodi A, Mezzanzanica M, Merlino L, Cesana G, Mancia G. Do socioeconomic disparities affect accessing and keeping antihypertensive drug therapy? Evidence from an Italian population-based study. J Hum Hypertens 2009; 23:238–244.
Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 2013; 165:665–678.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. for The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007; 25:1105–1187.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560–2572. Erratum in: JAMA. 2003;290:197.
Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012; 125:882–887. e1.
Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018; 72:846–853.
Mancia G, Rea F, Cuspidi C, Grassi G, Corrao G. Blood pressure control in hypertension. Pros and cons of available treatment strategies. J Hypertens 2017; 35:225–233.
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. List of authors/Task Force members. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2018; 36:2284–2309.
Mancia G, Rea F, Corrao G, Grassi G. Two-drug combinations as first-step antihypertensive treatment. Circ Res 2019; 124:1113–1123.
Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, Ferrucci A, et al. Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension. J Hypertens 2012; 30:1065–1074.
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158:915–920.
Moreno-Arellano S, Delgado-de-Mendoza J, Santi-Cano MJ. Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared to that in men. Nutr Metab Cardiovasc Dis 2018; 28:810–815.
Avgil Tsadok M, Jackevicius CA, Rahme E, Humphries KH, Pilote L. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015; 8:593–599.
Schmieder RE, Böhm M. Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. J Hum Hypertens 2011; 25:354–363.
Tadic M, Cuspidi C, Grassi G, Ivanovic B. Gender-specific therapeutic approach in arterial hypertension: challenges ahead. Pharmacol Res 2019; 141:181–188.
Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother 2017; 3:163–118.